

Supplemental Materials




Fig. S1 Respondents were asked when was the last time they recalled hearing the word 'biosimilar'




Fig. S2 Respondents were asked if they trust the FDA's decision to approve a biosimilar




Fig. S3 Respondents were asked to describe their clinical judgment of the concept of extrapolation




Fig. S4a




Fig. S4b




Fig. S4c




Fig. S4d




Fig. S4e

Fig. S4a-e Respondents were asked with which of the following statements they agree: A) To be approved as 'interchangeable' a biosimilar must be shown in patients to be safe and effective for back-and-forth switching with no negative impacts to safety or efficacy; B) When a biosimilar is approved for all the same indications as its originator brand counterpart, it means the biosimilar is 'interchangeable' with the brand; C) When the FDA approves a biosimilar as 'interchangeable,' that means it is okay for a pharmacist to dispense that product when I prescribe the brand; D) An 'interchangeable' biologic is a generic; and E) All biosimilars will be approved as 'interchangeable.' Statements A and C are correct




Fig. S5 Respondents were asked if they agree that immunogenicity can be adequately evaluated in non-clinical settings and fully understood before FDA approves a biosimilar




Fig. S6 Respondents were asked when biosimilars become available to their practice, where do they want to receive more information about each biosimilar?




Fig. S7 Respondents were asked where they current obtain information on biosimilars and which information source(s) are the most valuable and trustworthy




Fig. S8a




Fig. S8b

Fig. S8a-b Respondents were asked to rate their level of agreement with the following statements: A) “Biosimilars are important to the US healthcare system because they expand treatment options and provide savings to the healthcare system;” and B) “The entry of biosimilars into the US market may enable increased access and utilization of biologic medicines and thereby improve patient care.”




Fig. S9 Respondents were asked to rate their level of agreement with the following statement: "I would consider switching my patient to a biosimilar as an effective alternative to a similar therapeutic if it would help my patient have better access to his/her medications"